Stocktoria
NEKTAR THERAPEUTICS NKTR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1994-05-03
NEKTAR THERAPEUTICS statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| Net margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% |
| FCF margin | -377.8% | -180.0% | -214.7% | -336.4% | -419.6% |
| Return on assets | -58.5% | -39.2% | -69.4% | -51.8% | -46.9% |
| Return on equity | -182.6% | -195.9% | -210.8% | -100.4% | -77.1% |
| Current ratio | 4.97 | 4.26 | 6.45 | 8.00 | 9.34 |
| Revenue growth | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% |
Source: SEC EDGAR filings · CIK 0000906709 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.